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Patients with IgG4-related disease (IgG4-RD) share histopathological characteristics that are similar across aﬀected organs. The
ﬁnding of inﬁltration with IgG4+ plasma cells in the proper clinical and histopathological contexts connects a large number of
clinical entities that were viewed previously as separate conditions. The renal involvement in IgG4-RD is usually characterized
by tubulointerstitial nephritis, but membranous nephropathy has also been reported to be one of the renal complications of
IgG4-RD. The recent discovery that a high proportion of patients with idiopathic membranous nephropathy (IMN) have IgG4
autoantibodies to the M-type phospholipase A2 receptor (PLA2R) in the circulation and glomerular immune deposits, together
with the profound IgG4 hypergammaglobulinemia and occasional reports of membranous nephropathy in IgG4-RD, raised the
question of a common antigen. To assess the presence of anti-PLA2R antibody in patients with IgG4-RD, we screened sera from
28 IgG4-RD patients by immunoblot. None of the patients in this cohort had detectable circulating anti-PLA2R antibodies. This
study suggests that despite some clinical and serological overlaps between IgG4-RD and IMN,anti-PLA2R antibodies do not play
a role in the pathogenesis of IgG4-RD. Additional studies of IgG4-RD with evidence of membranous nephropathy are important
to exclude any deﬁnite relationship.
1.Introduction
IgG4-related disease (IgG4-RD) is a multiorgan system
ﬁbroinﬂammatory condition deﬁned by a tendency to form
tumorous lesions in various organs including the pancreas,
salivary and lacrimal glands, biliary tract, liver, lung, and
kidney, aorta [1]. The histopathologic ﬁndings are remark-
ably similar across all organs in this disease. The distinctive
pathologic features include a dense lymphoplasmacytic inﬁl-
trate rich in IgG4-positive plasma cells, storiform ﬁbrosis,
obliterative phlebitis, and eosinophilia [2]. Frequent eleva-
tionsofserumIgG4inpatientswithIgG4-RDandsigniﬁcant
clinical responses to glucocorticoids are other hallmarks of
this condition [3]. The relationship between elevated serum
IgG4 and distinctive patterns of organ involvement was ﬁrst
recognized in autoimmune pancreatitis [4], but subsequent
observations led to the identiﬁcation of this disease in nearly
all organ systems [1, 2, 5].
Idiopathic membranous nephropathy (IMN) is an
organ-speciﬁc autoimmune disorder and a leading cause of
nephrotic syndrome in adults. Until recently, the etiology
of this condition was unknown, but studies in experimental
MN had established that circulating antibodies bind to a
target antigen on glomerular podocytes and form antigen-
antibody complexes that cause podocyte injury and protein-
uria [6]. In 2009, Beck et al. discovered that a high propor-
tion of patients with IMN have circulating IgG4 autoanti-
bodies that bind to the M-type phospholipase A2 receptor
(PLA2R),atransmembraneglycoprotein,andmemberofthe
mannose receptor family expressed on human glomerular2 International Journal of Rheumatology
podocytes [7]. This ﬁnding is congruent with previous
reports that IgG4 predominates in the immune deposits of
renal biopsy specimens of IMN. This predominance of IgG4
isnotobservedinsecondary—orlupus-associated—membr-
anous nephropathy [8]. Studies of patients in several diﬀer-
entcohortshaveindicatedthat70–80%ofpatientswithIMN
have anti-PLA2R antibodies that are of the IgG4 subclass
[7, 9–11]. Of note, however, hypergammaglobulinemia and
elevated serumIgG4 concentrations are not reported in IMN
patients.
IgG4-RD and IMN both appear to respond well to B cell
depletion treatment with rituximab [9, 12, 13]. The early
experience with B cell depletion in IgG4-RD suggests that
rituximab (RTX) has a targeted eﬀect on serum IgG4:IgG4
decreasesrapidlyfollowingBcelldepletionwhiletheconcen-
trations of other IgG subclasses remain stable [12, 13]. RTX
has also been reported in case series to be eﬀective in IMN
[14, 15]. A decline in anti-PLA2R antibodies has been shown
to precede the clinical improvement of patients with mem-
branous nephropathy [9]. A randomized clinical trial of
RTX in IMN is now under way (Clinicaltrials.gov identiﬁer
NCT01180036).
Membranous nephropathy has been reported in some
patients with IgG4-RD [16–18], but the principal renal
manifestation of IgG4-RD is tubulointerstitial nephritis [19,
20], characterized by interstitial ﬁbrosis and inﬁltration of
lymphocytes and IgG4-positive plasma cells. Immune com-
plex deposition and membranous glomerulonephritis have
been shown to coexist with tubulointerstitial nephritis in a
minority of patients with IgG4-RD [21, 22]. Cravedi et al.
[23]recentlydescribedapatientwithIgG4-RDwhohadpan-
creatic and salivary gland involvement and subsequently
developed proteinuria. A renal biopsy showed features of
membranous nephropathy. A search for anti-PLA2R anti-
bodies in that patient’s serum was negative. Likewise, anti-
PLA2R antibodies were not detected in the case of IgG4-RD
and membranous nephropathy reported by Fervenza et al.
[18].
Because of certainclinical and pathological features of
IgG4-RD and IMN overlap, the shared association with anti-
bodies of the IgG4 subclass, and the ostensible improvement
that both diseases demonstrate in response to B cell deple-
tion, we assayed sera from patients in our longitudinal IgG4-
RD registry for antibodies directed against PLA2R.
2.MaterialandMethods
2.1. Patients. Between July 2009 and September 2011, we
obtained serum samples from 28 patients with IgG4-RD. All
patients were enrolled in the Massachusetts General Hospital
IgG4-RD Registry. The screening of human sera for anti-
PLA2R antibodies was approved by the Institutional Review
Boards at both the Massachusetts General Hospital and
Boston University Medical Center.
2.2. Inclusion Criteria for the IgG4-RD Registry. Patients were
eligible to participate in the study if they had a biopsy-
conﬁrmed diagnosis of IgG4-RD. Histopathologic features
considered to be highly suggestive of IgG4-RD diagnosis
included lymphoplasmacytic inﬁltrates and storiform ﬁbro-
sis within involved organs. Obliterative phlebitis and mild-
to-moderatetissueeosinophiliawereobservedfrequentlybut
were not required for the diagnosis [24]. In addition, all pa-
tients had either an IgG4/IgG plasma cell ratio of >50%
within the aﬀected organs or more than 30 IgG4-bearing
plasma cells/high-power ﬁeld (hpf). Elevated serum IgG4
was not required for the diagnosis of IgG4-RD.
2.3. IgG4 Plasma Cell Quantitation. Immunohistochemical
staining was performed as previously described [12]. For-
malin-ﬁxed, paraﬃn-embedded tissue sections were stained
with antibodies to IgG4 (Zymed, 1:200 dilution) or IgG
(Dako, 1:3000 dilution). For each specimen, the number of
IgG4+ plasma cells and the total number of IgG+ plasma
cellswereassessedinthreenonoverlappinghigh-powerﬁelds
(400x). The three ﬁelds with the highest number of IgG4+
plasma cells were selected for quantitation, and the ratio of
IgG4+/IgG+ plasma cells was determined.
2.4. Serum IgG4 Assay. Serum IgG4 concentrations were
measured by nephelometry (Mayo Medical Laboratories
New England, Andover, Massachusetts).
2.5. Immunoblot Assay for the Detection of Anti-PLA2R
Antibodies. Patients’ sera were tested for the presence of
anti-PLA2R antibodies by immunoblot, under nonreducing
conditions,aspreviouslydescribed[7].Recombinanthuman
PLA2R was fractionated by polyacrylamide gel electrophore-
sis and transferred to nitrocellulose membranes. Individual
lanes were cut and incubated overnight at 4◦Cw i t hs e r u m
samples diluted 1:25 in Tris-buﬀered saline containing 0.2%
Tween-20 and 10% skim milk. Serum from a patient with
IMN, previously shown to have anti-PLA2R antibodies,
was used as a positive control. IgG subclass-speciﬁc sheep
anti-human IgG4 (The Binding Site, San Diego, CA) was
used at 1:3000. Sheep IgG was subsequently detected with
species-speciﬁc, horseradish peroxidase-conjugated donkey
anti-sheep IgG (Jackson ImmunoResearch, West Grove, PA),
followed by reaction in a chemiluminescent substrate and
exposure to radiographic ﬁlm for two minutes. A band
corresponding to the size of PLA2R was judged to represent
the presence of anti-PLA2R antibodies.
3. Results
Demographic Features. Sera from 28 patients were tested for
thepresenceofanti-PLA2Rantibodies.Thepatients’baseline
characteristics are shown in Table 1.The IgG4-RD patients
i n c l u d e d1 5m e na n d1 3w o m e n ,w i t ha na v e r a g ea g eo f5 7
years (range: 24–82).
Clinical manifestations of IgG4-RD. The patients’ manifesta-
tions of IgG4-RD covered the full range of disease expression
[25],including clinicallyevident renaldiseasein twopatients
(see below). Multiorgan system IgG4-RD was observed in
11 patients (39%). The most commonly involved organsInternational Journal of Rheumatology 3
Table 1: IgG4-RD patients’ characteristics.
Patient Age Sex Serum IgG4
mg/dL
Serum IgG
mg/dL ANA Prednisonetreatment Organ involved
1 67 M 1340 2450 +1:1280S Yes aorta, lymph node
2 76 M 2050 2310 +1:40S Yes pancreas, biliary tract, aorta, lymph
node, salivary gland
3 55 M 1500 1640 +1:160S Yes lacrimal and salivary glands
4 51 F 401 726 +1:5120C Yes lacrimal and salivary glands
5 60 M 365 2570 +1:40S Yes aorta
6 58 M 894 1210 +1:40S No lymph node
7 41 M 200 766 +1:40H No lymph node
8 24 M 47 100 — Yes orbital tissue
9 72 F 429 1170 +1:320S Yes lacrimal & salivary glands Skin
10 52 F 62 1280 — Yes biliary tract
11 40 F 98 1090 +1:160S Yes pancreas, lung, thyroid, lacrimal gland
12 59 M 27 1280 +1:40S Yes retroperitoneum
13 48 F 9 1240 +1:40S No pericardium
14 63 M 386 1500 +1:40S Yes retroperitoneum, kidney
15 56 M 670 1980 +1:640H Yes orbital tissue
16 74 F 28 1830 +1:40S Yes kidney, lacrimal gland, pancreas, and
biliary tract
17 39 M 53 1460 +1:40S Yes retroperitoneum
18 51 F 68 1190 +1:40S No lymph node
19 33 F 139 1570 +1:160S No lymph node
20 58 F 194 1160 +1:40H Yes tonsils
21 41 F 240 1710 +1:160H No salivary gland
22 63 F 30 923 +1:320S Yes orbital tissue
23 51 F 80 1300 — Yes pachymeninges
24 82 M 59 1180 — No lymph node
25 66 F 154 769 +1:160S Yes retroperitoneum, lymph node, salivary
gland
26 72 M 12 1000 +1:40S Yes pancreas, salivary gland
27 70 M 164 1230 +1:160S Yes pancreas, biliary tract, salivary gland
28 61 M 50 1650 +1:160S Yes pancreas, retroperitoneum, hard palate,
lymph node
S: Speckled H: Homogeneous C: Centromere.
and tissues were the lymph nodes (n = 9), salivary glands
(n = 8), and orbital regions (n = 7). Five patients had IgG4-
related pancreatitis (type 1 AIP), and four had IgG4-related
sclerosing cholangitis. The other sites involved were the
retroperitoneum (n = 4), aorta (n = 3), and the skin, peri-
cardium, lung, thyroid gland, and tonsils (1 patient each).
Renal Disease. Two patients had evidence of kidney dysfunc-
tion, characterized by renal masses and proteinuria. Patient
16 [26] was found to have bilateral kidney masses on a
magnetic resonance imaging study performed for evaluation
of IgG4-related sclerosing cholangitis. Renal biopsy showed
a destructive tubulointerstitial inﬁltrate with prominent
ﬁbrosis. The inﬂammatory inﬁltrate was composed pre-
dominantly of IgG4+ plasma cells. There were signiﬁcant
quantities of electron dense deposits within the thickened
tubular basement membrane, and small electron-dense
deposits were seen scattered within the ﬁbrotic interstitium.
The glomeruli were free of deposits.
Patient 14 was diagnosed with IgG4-related retroperi-
toneal ﬁbrosis. Acute renal failure and proteinuria emerged a
year after the diagnosis of IgG4-RD and resolved with gluco-
corticoid treatment. Kidney biopsy showed tubular injury,
periglomerular ﬁbrosis, interstitial inﬂammation, and the
presence of IgG4+ plasma cells. Immunoﬂuorescence micro-
scopy showed no tubular basement membrane or glomeru-
lar basement membrane deposits. There were prominent
mesangial granular deposits of IgG, IgA, IgM, and C3.
Treatment before Serum Sampling. Most of the patients were
entered into the IgG4-RD Registry after the initiation of
prednisone treatment. Twenty-one (75%) of the 28 patients
were receiving glucocorticoids at the time their serum IgG4
was measured for the ﬁrst time. Fifteen (54%) of the 284 International Journal of Rheumatology
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Figure 1: Representative immunoblot demonstrating that sera
from patients with IgG4-RD (lanes 2–5) lack detectable reactivity
with rPLA2R. Serum from a patient with idiopathic membranous
nephropathy (lane 1) was used as a positive control.
patients had elevated serum IgG4. Among those patients
with elevated serum IgG4 concentrations at baseline, the
mean IgG4 was 640mg/dL (normal <135mg/dL). The mean
serum IgG4 concentration for all patients in the cohort was
342mg/dL. Among the seven patients who were not treated
with glucocorticoids before the diagnosis of IgG4-RD and
serum sampling, the mean IgG4 level was 230mg/dL.
OtherAutoantibodyTesting. Patientsweretestedforrheuma-
toid factor by nephelometry, which was positive in 2 patients
(7%). Antinuclear antibody (ANA) testing by immunoﬂu-
orescence using the HEp-2 substrate was positive in 24
patients (85%). Patient 4 had a strongly positive ANA in an
anticentromerepatternbuthadnoclinicalfeaturesoflimited
systemic sclerosis or Sj¨ ogren’s syndrome, and salivary gland
histopathology disclosed ﬁndings diagnostic of IgG4-RD,
not Sj¨ ogren’s syndrome. Enzyme-linked immunoabsorbent
assays for antibodies against Ro, La, Sm, and RNP antigens
were negative in all 28 patients.
Anti-PLA2R antibody assays. The sera from these 28 patients
with IgG4-RD were tested for the presence of autoantibodies
reactive with PLA2R. None of the serum samples contained
detectable anti-PLA2R antibodies when screened at a dilu-
tion of 1:25 (Figure 1).
4. Discussion
IgG4-RD and IMN have signiﬁcant overlap in their renal
manifestations. Although membranous nephropathy is most
often a renal limited autoimmune disease (so-called idio-
pathic or primary MN), membranous lesions and nephrotic
syndrome have also been reported in IgG4-RD [23]a n dm a y
accompany the more usual interstitial nephritis typical of
IgG4-RD [16, 27]. Both IgG-RD and IMN are associated
with perturbations in the IgG4 antibody subclass. The
autoantibody recently linked to IMN is generally of the IgG4
subclass, and IgG4 hypergammaglobulinemia—occasionally
present up to 25 times the upper limit of normal—occurs
in 70% of patients with IgG4-RD [28]. In addition, many
cases of both IMN and IgG4-RD are exquisitely sensitive
to treatment with rituximab. B cell depletion is associated
with declines in the titers of anti-PLA2R in IMN and the
level of IgG4 hypergammaglobulinemia in IgG-RD. Despite
the similarities between IMN and IgG4-RD, the principal
ﬁnding of this study is that the likelihood of a relationship
between IgG4-RD and autoantibodies to the PLA2R is low.
These antibodies were not identiﬁed in any of the 28 patients
evaluated in this study. The absence of anti-PLA2R in two
previous cases of IgG4-RD accompanied by membranous
nephropathy is noteworthy [18, 23].
There are a variety of potential explanations for this ﬁnd-
ing. The ﬁrst is that anti-PLA2R antibodies do not play a role
inIgG4-RDandthatadiﬀerentantigen-antibodysystemisat
play in those few cases that develop membranous nephropa-
thy[23].Thisisconsistentwiththefactthatalthoughimpor-
tant similarities exist between these two conditions, funda-
mental diﬀerences also exist. Whereas IMN is a renal-limited
lesion, IgG4-RD is a multiorgan disease [25]. IMN patients
do not demonstrate elevated serum IgG4 and decreased
complement levels which are seen in some patients with
IgG4-RD. Furthermore, although membranous GN has been
described in IgG4-RD, the renal lesion most characteristic
of IgG4-RD is tubulointerstitial nephritis. Finally, the other
pathological features that are central to IgG4-RD, namely,
storiform ﬁbrosis, obliterative phlebitis, and the inﬁltration
of large numbers of IgG4+ plasma cells are absent in IMN.
The glomerular lesions of IgG4-RD described to date have
included mesangial proliferative glomerulonephritis, mem-
branous nephropathy, membranoproliferative glomerulone-
phritis, and endocapillary proliferative glomerulonephritis
[19, 29].
A second possible explanation for our inability to detect
the anti-PLA2R antibodies in this IgG4-RD patient cohort
is that 75% of the patients received glucocorticoids prior to
their entry to the study. Although glucocorticoids may have
reduced the level of anti-PLA2R antibodies below the level of
detection by the immunoblot assay used in this study, they
are generally ineﬀective when used alone for treatment of
IMN. Moreover, we did not detect these antibodies even in
patients who had not been treated with glucocorticoids prior
to serum sampling (n = 7).
A third potential explanation for our failure to ﬁnd any
relationship between the presence of anti-PLA2R antibodies
and IgG4-RD is that IgG4-RD is not a single disease but
rather a pathologic syndrome in which certain mechanisms
operate across organ systems. If this explanation were true,
thenanti-PLA2Rantibodiesmightplayaroleinsomedisease
subsets of IgG4-RD, particularly the renal disease subset.
The renal disease subset of IgG4-RD is underrepresented in
our Registry as only two patients had overt renal disease,
and none had biopsy-proven membranous glomerulonephr-
opathy or nephrotic range proteinuria. An expanded study
that includes a larger number of IgG4-RD patients with renal
involvement of this nature is important to exclude deﬁni-
tively any relationship between IgG4-RD and antibodies to
the PLA2R.International Journal of Rheumatology 5
Given the consistency of pathological features across
involved organs in IgG4-RD, we believe that our ﬁndings
likely represent the true nature of the relationship between
IgG4-RD and antibodies to the PLA2-R, namely, that there
is none. The signiﬁcance of IgG4 hypergammaglobulinemia
andIgG4+plasmacellinﬁltrationintoinvolvedorgansinpa-
tients with IgG4-RD—whether they are pathogenic or just
“innocent bystanders”—remains to be clariﬁed.
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